Mirum Q2 update

  $37.5 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $32.5 million, for second quarter 2023

- Acquiring CHENODAL® and CHOLBAM®, advancing Mirum’s leadership in pediatric hepatology with a multi-product franchise
- Four late-stage clinical trial data readouts expected later this year
- Conference call to provide business updates August 3 at 1:30 p.m. PT/4:30 p.m. ET

Mirum will host a conference call today, August 3, 2023, at 1:30 p.m. PT/4:30 p.m. ET, to provide business updates. Join the call using the following details:

Conference Call Details:

U.S./Toll-Free: +1 833 470 1428
International: +1 404 975 4839
Passcode: 969043

You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.

https://finance.yahoo.com/news/mirum-pharmaceuticals-reports-second-quarter-200500140.html